Apigenin Blocks Liver Cell Death from Mold Toxin via Key Antioxidant Pathway
A natural plant flavonoid activates the Nrf2/FSP1 pathway to halt ferroptosis triggered by fumonisin B1, a common food contaminant.
Summary
Fumonisin B1 (FB1), a mycotoxin found in moldy grains, damages liver cells through ferroptosis — an iron-dependent form of programmed cell death. Researchers found that apigenin, a flavonoid abundant in parsley and chamomile, protects hepatocytes by activating the Nrf2/FSP1 antioxidant pathway. FB1 exposure reduced protective molecules like CoQ10H2 and FSP1 while increasing iron accumulation and lipid peroxidation. Apigenin reversed these effects similarly to a known ferroptosis inhibitor. When Nrf2 or FSP1 were genetically silenced, apigenin lost its protective benefit, confirming pathway dependency. This positions apigenin as a promising natural hepatoprotective agent against environmental mycotoxin exposure.
Detailed Summary
Mycotoxin contamination of food crops is a persistent global health concern, with fumonisin B1 (FB1) being among the most prevalent and hepatotoxic offenders. Despite widespread exposure through contaminated maize and grain products, the precise cellular mechanisms underlying FB1-induced liver damage have remained incompletely understood, and effective nutritional or pharmacological countermeasures have been lacking.
This study investigated whether ferroptosis — a regulated, iron-dependent cell death mechanism characterized by lipid peroxidation — plays a role in FB1 hepatotoxicity. Researchers exposed hepatocytes to FB1 and observed hallmark features of ferroptosis: elevated intracellular Fe2+ levels, increased lipid peroxidation (LPO), a raised NAD+/NADH ratio, and suppressed levels of ubiquinol (CoQ10H2), Nrf2 transcription factor, and ferroptosis suppressor protein 1 (FSP1).
Apigenin (AG), a natural plant-derived flavonoid, was tested for its ability to counteract these effects. AG treatment upregulated CoQ10H2 and suppressed lipid peroxidation, mirroring the protection seen with ferrostatin-1 (a pharmacological ferroptosis inhibitor) and with genetic overexpression of Nrf2 or FSP1. Critically, when either Nrf2 or FSP1 was knocked down, apigenin's hepatoprotective effects were abolished, demonstrating that the Nrf2/FSP1 axis is mechanistically required for its action.
These findings establish ferroptosis as a novel mechanism of FB1-induced liver injury and identify apigenin as a natural compound capable of engaging the Nrf2/FSP1 pathway to provide meaningful cellular protection.
Caveats include the study's reliance on cell-based models, with no in vivo validation reported in the abstract. Translation to human dietary contexts requires further dose-response and bioavailability studies.
Key Findings
- FB1 mycotoxin induces ferroptosis in hepatocytes via increased Fe2+, lipid peroxidation, and suppressed CoQ10H2/FSP1.
- Apigenin activates the Nrf2/FSP1 antioxidant pathway, restoring CoQ10H2 and reducing lipid peroxidation.
- Apigenin's protection matches that of ferrostatin-1 and Nrf2/FSP1 overexpression in potency.
- Knockdown of Nrf2 or FSP1 completely abolished apigenin's hepatoprotective effects, confirming pathway dependency.
- Ferroptosis is identified as a previously unrecognized mechanism in FB1-induced liver toxicity.
Methodology
The study used hepatocyte cell culture models exposed to FB1, with pharmacological inhibitors (ferrostatin-1), genetic overexpression, and gene knockdown of Nrf2 and FSP1. Key ferroptosis biomarkers measured included Fe2+, CoQ10H2, LPO, and NAD+/NADH ratio. This appears to be an in vitro study based on available abstract data.
Study Limitations
The study appears limited to in vitro hepatocyte models, with no animal or human data reported. Bioavailability and effective dosing of apigenin in vivo remain unaddressed. The abstract does not clarify whether effects were studied in human or animal-derived cell lines, limiting direct clinical extrapolation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.